Compare LDOS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LDOS | NTRA |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | United States |
| Employees | 48000 | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9B | 27.0B |
| IPO Year | 2006 | 2015 |
| Metric | LDOS | NTRA |
|---|---|---|
| Price | $187.48 | $244.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $204.91 | ★ $227.69 |
| AVG Volume (30 Days) | 751.8K | ★ 1.7M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 22.34 | N/A |
| EPS | ★ 10.68 | N/A |
| Revenue | ★ $17,332,000,000.00 | $2,116,676,000.00 |
| Revenue This Year | $5.17 | $32.77 |
| Revenue Next Year | $3.59 | $16.51 |
| P/E Ratio | $17.49 | ★ N/A |
| Revenue Growth | 6.48 | ★ 38.17 |
| 52 Week Low | $123.62 | $125.38 |
| 52 Week High | $205.77 | $245.59 |
| Indicator | LDOS | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 80.03 |
| Support Level | $186.27 | $233.67 |
| Resistance Level | $196.56 | $240.18 |
| Average True Range (ATR) | 4.19 | 7.39 |
| MACD | -0.23 | 0.68 |
| Stochastic Oscillator | 21.72 | 97.49 |
Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health markets, both domestically and internationally. Company customer includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in four reportable segments; National Security & Digital, Health & Civil, Commercial & International and Defense Systems. It provides a wide array of scientific, engineering and technical services and solutions across these reportable segments.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.